<DOC>
	<DOCNO>NCT01049919</DOCNO>
	<brief_summary>This trial evaluate safety efficacy concentrate bone marrow aspirate ( cBMA ) prevent delay major amputation and/or death subject critical limb ischemia ( CLI ) due severe peripheral arterial disease ( PAD ) .</brief_summary>
	<brief_title>Safety Efficacy Study Autologous Concentrated Bone Marrow Aspirate ( cBMA ) Critical Limb Ischemia ( CLI )</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo control , multicenter trial intend subject critical limb ischemia ( CLI ) unsuitable revascularization . The investigational treatment utilize autologous concentrate bone marrow aspirate ( cBMA ) point care . The bone marrow aspirate obtain subject 's hip , concentrate bone marrow concentration device , deliver intramuscularly affect limb . Subjects meet inclusion/exclusion criterion randomize receive either investigational treatment ( cBMA ) placebo control ( sham treatment ) .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Unilateral bilateral low extremity ischemia due advance peripheral arterial disease Unsuitable revascularization Minor tissue loss ( Rutherford Category 5 ) ischemic rest pain ( Rutherford Category 4 ) ABI ≤ 0.6 , TBI ≤ 0.4 , TcPO2 ≤ 50 mm Hg Competent give consent No current malignancy history previous malignancy within last five year , exception adequately treat nonmelanoma skin cancer ( evidence standard preventative cancer screening require ) Major tissue loss ( Rutherford Category 6 ) Diabetics oral insulin therapy uncontrolled untreated proliferative retinopathy ( evidence retinal exam require ) Poorly control diabetes mellitus HbA1C &gt; 10 % ( evidence HbA1C test require ) Uncompensated congestive heart failure ( New York Heart Association Class IV ) and/or condition preclude general anesthesia Myocardial infarction stroke within last 90 day Elevated liver function test ( AST ALT twice normal upper limit ) Renal disease ( creatinine &gt; 2.5 mg/dl ) chronic hemodialysis White blood cell count &lt; 3,000/µL &gt; 15,000/µL , platelet count &lt; 100,000/µL , hematocrit &lt; 32 % Topical growth hormone therapy within last 90 day , injected growth hormone therapy within last 180 day Disease central nervous system and/or condition impair cognitive function Two episode pulmonary embolus document DVT index leg history DVT index leg without evidence clot resolution Current infection index leg Pregnant woman ( negative urine pregnancy test require ) Lower extremity venous disease pit edema index leg Recent history ( 6 month prior screen ) bone marrow disease treatment medication procedure adversely affect bone marrow would prohibit transplantation Current osteomyelitis index leg Existing HIV diagnosis Organ transplant recipient Known terminal disease process life expectancy le one year Severe concomitant disease ( ) additional condition ( ) investigator feel constitute ( ) criterion exclusion particular subject Major amputation require within 30 day Inclusion clinical study may affect outcome study Uncorrected stenosis ( e ) great 50 % common and/or external iliac artery and/or common femoral artery index leg .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>CLI</keyword>
	<keyword>PAD</keyword>
	<keyword>PVD</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Limb Salvage</keyword>
	<keyword>Amputation</keyword>
	<keyword>Leg Pain</keyword>
</DOC>